title: The schizophrenia drug-treatment paradox: pharmacological treatment based on best possible evidence may be hardest to practise in high-income countries.
abstract: Most people with schizophrenia live in low- and middle-income countries in which clinicians/policy makers are not the first targets of marketing. Because it is years after a drug is first launched that the full effects become known with confidence, the evidence upon which to base practice in low- and middle-income countries may be less biased than that in richer nations.
authors.forename: Clive E
authors.initials: CE
authors.lastname: Adams
authors.forename: Prathap
authors.initials: P
authors.lastname: Tharyan
authors.forename: Evandro S F
authors.initials: ES
authors.lastname: Coutinho
authors.forename: T Scott
authors.initials: TS
authors.lastname: Stroup
mesh_terms: D019049:Developed Countries / Q000191:economics; D003906:Developing Countries / Q000191:economics; D006801:Humans; D012559:Schizophrenia / Q000188:drug therapy* / Q000191:economics